• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2008-2011 年加拿大医院分离的铜绿假单胞菌的药敏情况:CANWARD 研究。

Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals: CANWARD 2008-2011.

机构信息

Department of Medicine, Health Sciences Centre, Winnipeg, Manitoba, Canada.

出版信息

Diagn Microbiol Infect Dis. 2012 Aug;73(4):361-4. doi: 10.1016/j.diagmicrobio.2012.05.007. Epub 2012 Jun 12.

DOI:10.1016/j.diagmicrobio.2012.05.007
PMID:22694789
Abstract

Broth microdilution (Clinical and Laboratory Standards Institute) was used to evaluate the antimicrobial susceptibility of 1549 Pseudomonas aeruginosa clinical isolates collected in Canada between January 2008 and October 2011. The percentage of isolates susceptible was as follows: amikacin 92.0%, ceftazidime 83.5%, ciprofloxacin 74.3%, colistin 93.4%, gentamicin 76.8%, meropenem 82.7%, and piperacillin-tazobactam 83.6%. Antimicrobial susceptibility did not change significantly between 2008 and 2011, with the exception of increasing susceptibility to gentamicin (P < 0.0001).

摘要

肉汤微量稀释法(临床和实验室标准协会)用于评估 2008 年 1 月至 2011 年 10 月期间在加拿大收集的 1549 株铜绿假单胞菌临床分离株的抗菌药物敏感性。敏感分离株的百分比如下:阿米卡星 92.0%、头孢他啶 83.5%、环丙沙星 74.3%、黏菌素 93.4%、庆大霉素 76.8%、美罗培南 82.7%和哌拉西林他唑巴坦 83.6%。除了对庆大霉素的敏感性增加(P<0.0001)外,2008 年至 2011 年间抗菌药物敏感性没有显著变化。

相似文献

1
Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals: CANWARD 2008-2011.2008-2011 年加拿大医院分离的铜绿假单胞菌的药敏情况:CANWARD 研究。
Diagn Microbiol Infect Dis. 2012 Aug;73(4):361-4. doi: 10.1016/j.diagmicrobio.2012.05.007. Epub 2012 Jun 12.
2
Antimicrobial susceptibility of 2906 Pseudomonasaeruginosa clinical isolates obtained from patients in Canadian hospitals over a period of 8 years: Results of the Canadian Ward surveillance study (CANWARD), 2008-2015.对8年间从加拿大医院患者中分离出的2906株铜绿假单胞菌临床菌株进行的药敏试验:2008 - 2015年加拿大病房监测研究(CANWARD)结果
Diagn Microbiol Infect Dis. 2017 Jan;87(1):60-63. doi: 10.1016/j.diagmicrobio.2016.10.003. Epub 2016 Oct 7.
3
Integrating pharmacokinetics, pharmacodynamics and MIC distributions to assess changing antimicrobial activity against clinical isolates of Pseudomonas aeruginosa causing infections in Canadian hospitals (CANWARD).整合药代动力学、药效学和 MIC 分布,以评估加拿大医院感染的铜绿假单胞菌临床分离株对抗菌药物活性的变化(CANWARD)。
J Antimicrob Chemother. 2013 May;68 Suppl 1:i67-72. doi: 10.1093/jac/dkt028.
4
In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy.在接受抗假单胞菌治疗的医院获得性肺炎重症监护病房患者下呼吸道分离的铜绿假单胞菌菌株中,抗菌药物耐药性的体内发展。
Int J Antimicrob Agents. 2010 Dec;36(6):513-22. doi: 10.1016/j.ijantimicag.2010.08.005.
5
Characterization of Acinetobacter baumannii and meropenem-resistant Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-2009 study.加拿大鲍曼不动杆菌和耐美罗培南铜绿假单胞菌的特征:CANWARD 2007-2009 研究结果。
Diagn Microbiol Infect Dis. 2011 Mar;69(3):335-41. doi: 10.1016/j.diagmicrobio.2010.10.030.
6
Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian intensive care units as part of the Canadian National Intensive Care Unit study.作为加拿大国家重症监护病房研究的一部分,从加拿大重症监护病房患者中分离出的铜绿假单胞菌菌株的抗菌药敏性。
Diagn Microbiol Infect Dis. 2008 Jun;61(2):217-21. doi: 10.1016/j.diagmicrobio.2008.01.009. Epub 2008 Mar 4.
7
Antimicrobial resistance among clinical isolates of Pseudomonas aeruginosa from patients in a teaching hospital, Riyadh, Saudi Arabia, 2001-2005.2001 - 2005年沙特阿拉伯利雅得一家教学医院患者铜绿假单胞菌临床分离株中的抗菌药物耐药性
Jpn J Infect Dis. 2007 May;60(2-3):123-5.
8
[Pseudomonas aeruginosa: antimicrobial resistance in clinical isolates. Castellón 2004-2008].[铜绿假单胞菌:临床分离株中的抗菌药物耐药性。卡斯特利翁,2004 - 2008年]
Rev Esp Quimioter. 2010 Mar;23(1):20-6.
9
Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.美国最佳耐药性监测计划国际网络四年(2012年至2015年)期间铜绿假单胞菌的抗菌药敏结果
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02252-16. Print 2017 Mar.
10
Antimicrobial susceptibility pattern of clinical isolates of Pseudomonas aeruginosa in a tertiary care hospital.一家三级护理医院中铜绿假单胞菌临床分离株的抗菌药敏模式
J Microbiol Immunol Infect. 2007 Feb;40(1):45-9.

引用本文的文献

1
Prevalence of colistin resistance in clinical isolates of : a systematic review and meta-analysis.临床分离株中黏菌素耐药性的流行情况:一项系统评价和荟萃分析。
Front Microbiol. 2024 Oct 9;15:1477836. doi: 10.3389/fmicb.2024.1477836. eCollection 2024.
2
MIC score, a new tool to compare bacterial susceptibility to antibiotics application to the comparison of susceptibility to different penems of clinical strains of Pseudomonas aeruginosa.MIC评分是一种用于比较细菌对抗生素敏感性的新工具,应用于比较铜绿假单胞菌临床菌株对不同碳青霉烯类抗生素的敏感性。
J Antibiot (Tokyo). 2016 Nov;69(11):806-810. doi: 10.1038/ja.2016.38. Epub 2016 Mar 30.
3
Kisameet Clay Isolated from the Central Coast of British Columbia, Canada, Demonstrates Broad-Spectrum Antimicrobial Activity.
从加拿大不列颠哥伦比亚省中部海岸分离出的基萨米特黏土具有广谱抗菌活性。
mBio. 2016 Mar 8;7(2):e00169. doi: 10.1128/mBio.00169-16.
4
Outcomes in Documented Pseudomonas aeruginosa Bacteremia Treated with Intermittent IV Infusion of Ceftazidime, Meropenem, or Piperacillin-Tazobactam: A Retrospective Study.间歇性静脉输注头孢他啶、美罗培南或哌拉西林-他唑巴坦治疗已记录的铜绿假单胞菌血症的疗效:一项回顾性研究。
Can J Hosp Pharm. 2015 Sep-Oct;68(5):386-94. doi: 10.4212/cjhp.v68i5.1485.
5
In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.2007 年至 2012 年加拿大 CANWARD 研究中,从加拿大医院患者分离的铜绿假单胞菌对头孢洛扎-他唑巴坦的体外活性。
Antimicrob Agents Chemother. 2013 Nov;57(11):5707-9. doi: 10.1128/AAC.01404-13. Epub 2013 Aug 12.